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Intrathecal enzyme replacement for Hurler syndrome:
biomarker association with neurocognitive outcomes
Julie B. Eisengart, PhD 1, Elizabeth I. Pierpont, PhD 1, Alexander M. Kaizer, PhD2,
Kyle D. Rudser, PhD3, Kelly E. King, PhD1, Marzia Pasquali, PhD4, Lynda E. Polgreen, MD 5,
Patricia I. Dickson, MD5,7, Steven Q. Le, BS5,7, Weston P. Miller, MD6,8, Jakub Tolar, MD, PhD6,
Paul J. Orchard, MD 6 and Troy C. Lund, MD, PhD 6
Purpose: Abnormalities in cerebrospinal fluid (CSF) have been
reported in Hurler syndrome, a fatal neurodegenerative lysosomal
disorder. While no biomarker has predicted neurocognitive
response to treatment, one of these abnormalities, glycosaminogly-
can nonreducing ends (NREs), holds promise to monitor
therapeutic efficacy. A trial of intrathecal enzyme replacement
therapy (ERT) added to standard treatment enabled tracking of
CSF abnormalities, including NREs. We evaluated safety, biomarker
response, and neurocognitive correlates of change.
Methods: In addition to intravenous ERT and hematopoietic cell
transplantation, patients (N= 24) received intrathecal ERT at four
peritransplant time points; CSF was evaluated at each point.
Neurocognitive functioning was quantified at baseline, 1 year, and 2
years posttransplant. Changes in CSF biomarkers and neurocogni-
tive function were evaluated for an association.
Results: Over treatment, there were significant decreases in CSF
opening pressure, biomarkers of disease activity, and markers of
inflammation. Percent decrease in NRE from pretreatment to final
intrathecal dose posttransplant was positively associated with
percent change in neurocognitive score from pretreatment to 2
years posttransplant.
Conclusion: Intrathecal ERT was safe and, in combination with
standard treatment, was associated with reductions in CSF
abnormalities. Critically, we report evidence of a link between a
biomarker treatment response and neurocognitive outcome in
Hurler syndrome.
Genetics inMedicine (2019) 21:2552–2560; https://doi.org/10.1038/s41436-
019-0522-1
Keywords: mucopolysaccharidosis; biomarkers; enzyme replace-
ment therapy; neurocognitive decline; intrathecal therapy
INTRODUCTION
Neurocognitive decline, a distinguishing symptom of the
severe form of mucopolysaccharidosis type I (MPS I), is
quantified in very young affected children by successive losses
in early IQ points. The pathogenesis of this decline is not
completely understood but has long been an area of
investigation and theory development.1–4 Besides neurocog-
nitive decline, severe MPS I (Hurler syndrome, MPS IH,
OMIM 607014) is distinguished from the attenuated pheno-
types by its early lethality, as the natural history of severe MPS
I involves death within the first decade of life.5,6 MPS I is an
autosomal recessive disorder caused by pathogenic variants in
the IDUA gene, resulting in insufficient production of α-L-
iduronidase, a lysosomal enzyme critical to degrading long
chains of sugar, or glycosaminoglycans (GAG).5 In all
phenotypes of MPS I, including Hurler syndrome and the
attenuated forms, accumulating GAG in nearly all organ
systems both directly and indirectly2,7–9 causes worsening
cardiac and pulmonary dysfunction, hepatosplenomegaly,
bone and joint disease, ophthalmologic and auditory
problems, and increased risk for central nervous system
(CNS) complications such as hydrocephalus and cervical
spinal cord compression.
Current recommended treatment for Hurler syndrome is
hematopoietic cell transplantation (HCT), which arrests
neurocognitive decline, halts accumulating somatic burden
in many organ systems, and prevents early death by providing
a stable source of enzyme via donor-derived cells of
hematopoietic origin.10–13 Deficient enzyme can also be
supplemented with intravenous recombinant iduronidase,
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i.e., enzyme replacement therapy (ERT). Intravenous ERT is
presumed to be unable to penetrate the blood–brain barrier to
treat the CNS manifestations of Hurler syndrome,8,14 but it is
used as an adjunct to HCT to decrease morbidity and
mortality.15–17 For most patients with Hurler syndrome,
neurocognitive outcomes include IQ scores that are below the
average range even following successful HCT.12,13,18 This
persistent neurocognitive morbidity is often the target of
innovative therapies for neurodegenerative MPS types,
through increasing enzyme in the CNS.14,19–23
However, existing therapies and those in trial all suffer from
a serious lack of precision in predicting neurocognitive
outcomes. There has been considerable emphasis on identify-
ing biomarker correlates of therapeutic outcomes, but to date
no biomarker has shown accurate, reliable clinical correspon-
dence with neurocognitive course.3,14 GAG levels in urine or
serum may be different between severe and attenuated
phenotypes, but not to a degree to distinguish phenotype
reliably,8,24 nor does urine or serum GAG level predict
neurocognition with any precision. Of the three major GAG
chains, including heparan sulfate, keratan sulfate, and
dermatan sulfate, accumulation of heparan sulfate has been
implicated in neurocognitive abnormalities.2,3,5 Recently a
focus on the predictable degradation of GAG starting with the
nonreducing end (NRE) of the chains led to development of a
methodology for quantifying disease-specific biomarkers from
these NREs.25 It was proposed that this method be used for
monitoring treatment efficacy. This proposal could be tested
when our phase I trial of intrathecal (IT) administration of
ERT for Hurler syndrome presented the unique opportunity
to obtain serial samples of cerebrospinal fluid (CSF) to
analyze for potential biomarker response, including elevated
heparan sulfate–derived NREs. We examined whether
observed NRE changes were associated with change in
neurocognitive function in the first two years following
treatment. This trial (NCT00638547) involved standard of
care at the University of Minnesota (i.e., peritransplant
intravenous ERT as an adjunct to HCT), with the addition of
IT ERT as means of “bridge therapy” between diagnosis and
the anticipated time to achieve donor-derived microglial
engraftment in the brain. The present study evaluated safety
of IT ERT, monitored alterations in CSF abnormalities at each
time point that IT enzyme was delivered, and measured
neurocognitive functioning prospectively to assess for clinical
correlates of biochemical change.
MATERIALS AND METHODS
Patient eligibility and study design
This was part of a two-year, single center, open label phase I
trial of IT ERT as adjunctive therapy to intravenous ERT and
HCT in Hurler syndrome. Schedule of therapies, biomarker
sampling, and neurocognitive evaluations is depicted in
Figure S1. Patients were eligible for study enrollment if they
(1) had a diagnosis of Hurler syndrome, (2) were aged
>6 months and <4 years, (3) were under consideration for
HCT at our center, and (4) had received ≤4 previous doses of
intravenous ERT. Among the 39 patients with Hurler
syndrome evaluated for HCT at the University of Minnesota
during the study period (2008–2014), 12 did not meet
inclusion criteria and 1 declined the addition of IT ERT to the
standard HCT protocol. Thus 26 patients were enrolled to
receive IT ERT in the peri-HCT period (Figure S2). One
patient withdrew due to poor cardiac function detected prior
to IT therapy, and a second received one dose of IT ERT and
elected to undergo HCT at another institution and withdrew
from the study. All patients also received concomitant
intravenous ERT as described below. Lumbar puncture with
CSF collection was performed at each IT infusion time point
by one of the authors (J.T., W.P.M., P.J.O., T.C.L.). All
therapies were administered by one of the authors (J.T., W.P.
M., P.J.O., T.C.L.). This study was approved by the
Committee on the Use of Human Subjects in Research at
the University of Minnesota. This protocol was reviewed and
approved by the FDA (IND 100782). This trial was registered
at www.clinicaltrials.gov as NCT00638547. Informed consent
was obtained from all legal guardians.
Intrathecal enzyme replacement administration
IT ERT was administered by standard lumbar puncture using
sterile technique. At each time point, recombinant iduroni-
dase (0.05 mg/kg) was delivered over 1–2 minutes in 4 mL of
Elliott’s B® solution. Infusion of IT ERT was planned at four
discrete time points with respect to HCT: 8–12 weeks before
HCT, 2 weeks before HCT, 100 days after HCT, and 6 months
after HCT (Figure S1). The timing coincided with scheduled
sedation. Dosing every 3 months was based on the experience
in the MPS I canine model.26 For both time points pre-HCT,
IT ERT was given prior to commencing the transplant
preparative regimen. In two instances, patients received
intravenous ERT prior to the first IT ERT dose.
Allogeneic hematopoietic stem cell transplantation
Transplant allografts were selected according to institutional
guidelines and based upon donor–recipient human leukocyte
antigen matching characteristics. Stem cell sources included
unrelated umbilical cord blood (n= 21), unrelated donor
marrow (n= 2), and noncarrier sibling donor marrow (n= 1).
All 24 patients underwent a myeloablative, busulfan-based
preparative regimen. Of those, 20 were treated with alemtu-
zumab (0.9 mg/kg), cyclophosphamide (200mg/kg), and
busulfan (targeted total area-under-the-curve exposure
[AUC] of 75 mg × hour/mL). The remaining four patients
received thymoglobulin (10mg/kg), fludarabine (160mg/m2),
and busulfan (targeted total AUC of 90mg/hour/mL).
Twenty-three patients successfully engrafted; one did not
and was retransplanted 6 weeks later, with reduced intensity
preparative regimen including fludarabine, busulfan, and total
body irradiation. Both times this patient's stem cell sources
were umbilical cord blood; engraftment was successful upon
second HCT.
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Peritransplant intravenous recombinant iduronidase
administration
All patients were treated with peritransplant intravenous ERT
(0.58 mg/kg, once weekly) per institutional guidelines;
patients received an average of 12 doses pretransplant and 8
doses posttransplant.
Cerebrospinal fluid evaluation
During the initial evaluation and subsequent IT delivery time
points, a lateral decubitus lumbar puncture was performed
with an opening pressure measurement; CSF was obtained
and analyzed for cell count, protein concentration, glucose
concentration, and biomarker analysis. End tidal CO2 was
monitored and maintained from 25–40 mm Hg to ensure
opening pressure accuracy. Methodology for biomarker
analysis is presented in the supplementary information
(Table S1). For protein and glucose concentrations and
biomarker analysis, comparison ranges were based on
previously published findings for unaffected controls whose
CSF was compared with that of patients with Hurler
syndrome.27
Neurocognitive assessment
A standard neurocognitive evaluation protocol previously
described18 was used for all patients at baseline (before any
intervention, except for two patients who had received prior
intravenous ERT) and after HCT at annual visits to the
University of Minnesota. The neurocognitive evaluations
included a test of developing intellectual function: the Mullen
Scales of Early Learning28 or the Bayley Scales of Infant and
Toddler Development, Third Edition.29 Both of these tests
yield a norm-referenced score that reflects overall neurocog-
nitive functioning (emerging IQ). Specifically, the IQ is
represented by age-based standardized scores with a popula-
tion mean of 100 and standard deviation of 15, with
qualitative ranges of average (85–115), below average
(70–84), and impaired (<70).
Statistics
Design and analyses followed an intention to treat approach
as all study patients received all therapies. Continuous
measures were summarized as mean (standard deviation)
along with median (interquartile range [IQR]) and categorical
measures as frequency (%). The change in mean biomarker
from time point 1 to subsequent time points was evaluated
using generalized estimating equations with exchangeable
working correlation structure and robust variance estimation
for confidence intervals and p value.30 A Wald test from
nested models was also used to evaluate if a mean biomarker
at any time point varied significantly from the other time
points. Additionally, the pairwise comparisons between time
point 1 and time points 2, 3, and 4 were adjusted for multiple
comparisons using the Benjamini–Hochberg correction.
Comparison of baseline IQ scores of patients with missing
versus complete data was evaluated with generalized estimat-
ing equations assuming independence working correlation
structure for baseline IQ. The association between biomarkers
and percent change in IQ was evaluated using generalized
estimating equations with independence working correlation
structure and robust variance estimation for confidence
intervals and p values. These analyses were conducted using
R v3.4.3 (R Foundation for Statistical Computing, Vienna,
Austria).
RESULTS
Patients and safety
Characteristics of the 24 patients who entered the trial are
summarized in Table 1. There were five deaths, all following
HCT: one due to myocardial infarction, one due to mycotic
thrombus, one from influenza A, and two from respiratory
failure (presumed viral pneumonia). None of the deaths were
attributed to IT ERT. There were no adverse events related to
IT ERT. An exact binomial test comparing survival within our
study sample with the 84% survival rate in a large modern
cohort31 indicated no difference in rates of survival (p=
0.574).
Cerebrospinal fluid evaluation
The CSF opening pressure, total protein, glucose, red cell
count, and white cell count were measured at the time of IT
ERT infusion. The upper limit of normal opening pressure in
a child is 20 cm H2O;
32 the mean opening pressure in Hurler
syndrome patients prior to ERT therapy was 24.2 cm H2O
(SD= 7.4), which decreased over the treatment period (Fig. 1,
Table 2). When changes in opening pressure were analyzed
(Table 2), the reduction of 4.5 cm H2O was significant from
time point 1 to 2, i.e., prior to any intervention to just before
HCT, reflecting change based on a single dose of IT enzyme
and concurrent intravenous enzyme (p= 0.0499). Overall
there was clinically significant variability in opening pressure
over the full treatment period (p= 0.0003). Mean opening
pressure decreased from time point 1 to 3 (p= 0.0004), before
increasing again at time point 4, such that it was not
significantly different from time point 1 (p= 0.0861). Mean
concentrations of CSF total protein did not significantly
vary between any time point (p= 0.7760; Table 2), but
mean concentrations of CSF glucose did vary significantly
(p= 0.0150; Table 2).
Table 1 Patient characteristics: values expressed are mean
(SD) and median (IQR) for continuous measures or N (%) for
categorical measures
Covariate (N) Mean (SD) Median (IQR)
(Total N= 24)
Male 12 (50.0%)
Age at transplant (months) (N= 24) 16.3 (6.17) 15.1 (12.8, 18.9)
IQ (M= 100 ± 15):
Baseline (N= 22) 84.6 (13.4) 86.0 (73.5, 97.0)
Year 1 (N= 18) 76.7 (16.8) 78.5 (65.5, 90.8)
Year 2 (N= 15) 79.1 (18.5) 79.0 (69.5, 90.5)
IQR interquartile range.
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Biochemical abnormalities within the CSF included bio-
markers of disease activity (NREs, total heparan sulfate [HS],
heparin cofactor II–thrombin complex [HCIIT]) and inflam-
matory factors (SDF1a, IL-1ra, MCP-1, and MIP-1b;
Table S2), all of which we previously found to be elevated
in treatment-naïve patients with Hurler syndrome.27 The
heparan sulfate NREs I0S0 and I0S6 separately showed
significant reductions at each time point and overall (p <
0.0001 for each; Table 2; Fig. 2). The reduction in mean NRE
I0S0 was more than 80% from time point 1 to 4, while for
NRE I0S6 it was approximately 54% for this same time span.
Some patients had undetectable NRE I0S0 at time point 4
(100% reduction). These observations of significant decre-
ments in each NREs I0S0 and I0S6 include the span prior to
HCT, i.e., time points 1 and 2 (p < 0.0001 for both; Table 2).
Evaluation of HS showed a significant drop, approximately
30%, between time points 1 and 4 (p= 0.0001; Table 2,
Fig. 2), but only a decrease of 7% between time points 1 and 2
(p= 0.3008; Table 2). Baseline HCIIT values were elevated in
the CSF, consistent with prior observations.27 There was a
significant HCIIT decrement by about a third between time
points 1 and 2, as well as an overall decrease by more than
half between time points 1 and 4 (p < 0.0001, Table 2, Fig. 2).
Although most patients did not have CSF antidrug antibodies
(ADA) at time point 1, 87% (i.e., 20/23) of patients showed a
transient increase in antibody detection at time point 2.
Almost universally, the CSF had little to no detectable
antibody at time points 3 and 4, i.e., post-HCT (Table 2).
MPS disease has been shown to have an inflammatory
component, in both the brain and bones.1–3 This includes
previous findings of elevated CSF cytokines in this patient
cohort when still treatment naïve.27 In the current study,
cytokines were able to be assayed in ten patients. The levels of
SDF1a, IL-1ra, MCP-1, and MIP-1b (Table S2) were taken at
serial time points, and the mean concentrations of SDF1a and
IL-1ra were not significantly different over time (p= 0.5378
and p= 0.2759, respectively; Table 2). However, MCP-1
and MIP-1b varied significantly over time (p= 0.0006 and
p= 0.0070, respectively) with their mean values decreasing
from time point 1 to 4 (p= 0.0124 and p= 0.0161,
respectively; Table 2).
To identify whether a strong response for one biomarker
(e.g., I0S6) was also reflected in responsiveness of other
biomarkers within the same patient, we conducted Pearson
correlations for percent decrease for each measure in Table 2.
Within patient, percent decrease of NRE I0S6 was strongly
correlated with percent decrease of I0S0 and heparan sulfate,
as expected given that both I0S6 and I0S0 are derived from
this GAG (Table S3). Within patient, percent decrease of I0S6
was negatively correlated with percent decrease of MCP-1 and
SDF1, suggesting they increase relative to the decrease in I0S6.
However, many correlations were smaller and suggest that a
good response (in % decrease) may not necessarily reflect a
linear change in other measures.
Neurocognitive outcomes
Neurocognitive outcomes, henceforth referred to as IQ scores,
at 1 and 2 years after HCT were compared with baseline (i.e.,
pretreatment) scores. Of the 24 patients treated with all four
doses of IT therapy, 22 had baseline neurocognitive assess-
ment data and 15 had neurocognitive assessment data at all
three time points (Table 1). There was no difference in
baseline IQ scores between the 15 who had complete data at
all time points and the 7 who had missing data (p= 0.1428).
The mean baseline IQ score was 84.6 (SD= 13.4; N= 22),
which is on the boundary between average and below average
(normative mean ± SD = 100 ± 15). At 2 years post-HCT, the
mean IQ was below average at 79.1 (SD= 18.5; N= 15).
Neurocognitive outcomes at 2 years post-HCT were examined
for a possible association with attenuating NRE; inflammatory
markers were subject to exploratory evaluation. Loss of IQ
points is generally reported following HCT;13,18,33 therefore,
results that are closer to no loss (quantified as zero percent
change), or even gain (quantified as a positive percent
change), are considered to reflect a favorable neurocognitive
trajectory of development. More specifically, percent change
in IQ is a continuous variable that is considered more
favorable when values approach a positive number, and less
favorable when values approach a negative number. Percent
decrease in NRE I0S6 from time point 1 to 4 was positively
associated with more favorable neurocognitive development
(i.e., percent change in IQ) from baseline to 2 years post-HCT
(Fig. 3). Decrease in I0S6 over the four time points is depicted
in the supplementary information (Figure S3). A more
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Fig. 1 Change in cerebrospinal fluid opening pressure throughout
treatment. Cerebrospinal fluid opening pressure on lumbar puncture
decreased significantly from time point 1 to 2, i.e., prior to transplant
(p= 0.0499). At time point 3, which is 100 days posttransplant, the
opening pressure was also significantly lower than time point 1
(p= 0.0004). Opening pressure increased somewhat at time point 4, which
is 6 months posttransplant, such that it was no longer significantly different
from time point 1 (p= 0.0861).
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Table 2 Comparison of mean measures across all time points and pairwise comparisons for changes from time point 1 to
follow-up time points
Time point Mean (SD) Δ From time point 1 (95% CI) p value
Opening pressure (cm H2O; ref range ≤ 20 cm H2O) (ref.
32)
1 (N= 23) 24.2 (7.4) - -
2 (N= 23) 19.7 (5.3) −4.5 (−8.6, −0.4) 0.0499
3 (N= 20) 18.5 (3.7) −5.7 (−8.6, −2.8) 0.0004
4 (N= 19) 21.0 (3.7) −3.2 (−6.8, 0.5) 0.0861
Any time point - - 0.0003
CSF protein (mg/dL; non-MPS ref 15–60mg/dL (ref. 27)
1 (N= 23) 31.0 (13.9) - -
2 (N= 24) 30.8 (10.7) −0.3 (−5.4, 4.7) 0.8951
3 (N= 20) 33.9 (12.6) 2.2 (−3.7, 8.1) 0.8951
4 (N= 21) 33.0 (15.9) 1.1 (−6.7, 8.9) 0.8951
Any time point - - 0.7760
CSF glucose (mg/dL; non-MPS ref 40–70mg/dL (ref. 27)
1 (N= 23) 48.8 (4.8) - -
2 (N= 24) 46.2 (5.3) −2.6 (−4.3, −1.0) 0.0058
3 (N= 21) 48.7 (7.2) −0.1 (−2.4, 2.3) 0.9536
4 (N= 21) 51.0 (8.8) 2.3 (−1.6, 6.2) 0.3834
Any time point - - 0.0150
CSF antidrug antibodies
1 (N= 23) 0.012 (0.041) - -
2 (N= 23) 0.082 (0.085) 0.069 (0.034, 0.104) 0.0003
3 (N= 20) 0.003 (0.003) −0.009 (−0.024, 0.006) 0.2534
4 (N= 19) 0.002 (0.002) −0.010 (−0.026, 0.005) 0.2534
Any time point - - <0.0001
I0S6 (ng/mL; non-MPS ref < 30 ng/mL (ref. 27)
1 (N= 20) 240.4 (100.4) - -
2 (N= 20) 157.9 (76.6) −82.5 (−112.2, −52.8) <0.0001
3 (N= 20) 127.2 (55.5) −113.2 (−145.9, −80.5) <0.0001
4 (N= 20) 110.1 (45.9) −130.3 (−166.0, −94.6) <0.0001
Any time point - - <0.0001
I0S0 (ng/mL; non-MPS ref < 15 ng/mL (ref. 27)
1 (N= 20) 58.2 (32.0) - -
2 (N= 20) 29.9 (15.4) −28.3 (−42.0, −14.6) <0.0001
3 (N= 20) 16.8 (12.8) −41.5 (−56.9, −26.0) <0.0001
4 (N= 20) 11.2 (10.6) −47.1 (−61.2, −32.9) <0.0001
Any time point - - <0.0001
Heparan sulfate (ng/mL; non-MPS ref < 120 ng/mL (ref. 27)
1 (N= 20) 283.7 (99.5) - -
2 (N= 20) 262.9 (80.9) −20.8 (−60.1, 18.6) 0.3008
3 (N= 20) 212.9 (83.8) −70.8 (−118.0, −23.5) 0.0050
4 (N= 20) 195.1 (60.2) −88.6 (−131.2, −46.0) 0.0001
Any time point - - 0.0001
Heparin cofactor II–thrombin (ng/mL; non-MPS ref < 0.25 ng/mL (ref. 27)
1 (N= 21) 7.1 (3.1) - -
2 (N= 23) 4.8 (3.5) −2.3 (−3.6, −1.0) 0.0006
3 (N= 21) 2.8 (1.9) −4.4 (−5.7, −3.1) <0.0001
4 (N= 21) 3.3 (3.1) −3.8 (−5.7, −2.0) <0.0001
Any time point - - <0.0001
MCP-1 (pg/mL; no reference range (ref. 27)
1 (N= 10) 976.7 (401.1) - -
2 (N= 10) 891.4 (526.7) −85.3 (−257.5, 86.9) 0.3317
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Table 2 continued
Time point Mean (SD) Δ From time point 1 (95% CI) p value
3 (N= 10) 760.9 (197.2) −215.8 (−477.2, 45.6) 0.1586
4 (N= 10) 595.7 (169.5) −381.0 (−641.5, −120.5) 0.0124
Any time point - - 0.0006
MIP-1b (pg/mL; no reference range27)
1 (N= 10) 15.0 (7.0) - -
2 (N= 10) 10.8 (3.6) −4.2 (−7.5, −0.9) 0.0205
3 (N= 10) 14.1 (7.2) −0.9 (−6.3, 4.5) 0.7370
4 (N= 10) 9.0 (4.8) −6.0 (−10.2, −1.8) 0.0162
Any time point - - 0.0070
SDF1 (pg/mL; no reference range27)
1 (N= 10) 385.1 (94.7) - -
2 (N= 10) 351.7 (123.0) −33.3 (−144.9, 78.2) 0.8374
3 (N= 10) 334.9 (168.7) −50.1 (−179.4, 79.2) 0.8374
4 (N= 10) 387.7 (303.1) 2.6 (−192.5, 197.8) 0.9788
Any time point - - 0.5378
IL-1Ra (pg/mL; no reference range27)
1 (N= 10) 18.7 (6.6) - -
2 (N= 10) 25.0 (32.7) 6.3 (−12.8, 25.3) 0.5203
3 (N= 10) 34.1 (33.5) 15.3 (−3.1, 33.8) 0.2497
4 (N= 10) 32.0 (31.8) 13.2 (−5.5, 31.9) 0.2497
Any time point - - 0.2759
CI confidence interval, CSF cerebrospinal fluid, MPS mucopolysaccharidosis.
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intrathecal recombinant iduronidase infusion, 6 months posttransplant. All
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IQ (p= 0.0035). CI confidence interval.
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favorable percent change in IQ by 2 years post-HCT was also
associated with lower levels of NREs I0S0 and I0S6 at time
point 3 (p < 0.0001 and p= 0.0078, respectively) and NRE
I0S6 at time point 4 (p= 0.0054). Decrease in NRE I0S0 from
time point 1 to 4 was not associated with IQ change. CSF
MCP-1 at time point 4 was plotted with change in IQ, and the
resulting scatterplot showed a rather clear slope suggestive of
a relationship. However, this was a small subset of the sample,
as only seven participants had both MCP-1 and IQ assessed
and therefore a meaningful statistical evaluation could not be
performed. Statistical evaluations were not performed on the
relationship between IQ change and any inflammatory
markers for this reason.
DISCUSSION
This study systematically tracked changes in CSF character-
istics during this novel treatment with IT ERT, which was
added to standard dual therapy of HCT with peritransplant
intravenous ERT. This therapy was safe and well tolerated,
and deaths on this study resulted from HCT-related
morbidity and not IT enzyme infusion. Although mortality
was slightly higher than reported in recent trials,6,31 this
difference was not statistically meaningful. Causes of death
matched previous reports of HCT-related mortality,31 includ-
ing infection in four of the five cases, suggesting tragic chance
was to blame rather than the therapy protocol. Of import, the
method of therapy delivery in this protocol enabled the
unusual opportunity to evaluate serial samples of CSF to track
potential treatment response. This tracking revealed signifi-
cant decreases in CSF opening pressure as well as biomarkers
including heparan sulfate NREs, HCIIT, and several inflam-
matory cytokines across all time points. Among these reduced
biomarkers were NREs, recently proposed as tools for
monitoring treatment efficacy.25 In an urgent hunt for more
precise methods of predicting treatment outcomes, the
present study’s findings that greater reduction in an NRE
was associated with a more favorable neurocognitive trajec-
tory has important implications. This potential link between a
biochemical response during treatment and a longer-term
neurocognitive outcome in Hurler syndrome may support
understanding disease pathophysiology and optimizing
patient management.
Neurocognitive decline in patients with Hurler syndrome
continues for a period after HCT, then stabilizes.13,18,33 Earlier
age at treatment predicts a significantly better neurodevelop-
mental course.8,12,13,34,35 Presumably, treatment at an earlier
age reduces brain injury resulting from pathophysiological
processes such as inflammation, oxidative stress, and other
disruptions to intracellular and extracellular homeostasis.2,3
However, predicting neurocognitive status based on timing of
treatment is unreliable due to numerous factors that can
influence outcomes. In the current study, several patients
showed an increase in IQ scores after therapy, demonstrating
gains not only relative to their own development but also
relative to the normative population. This is a dramatic
outcome given the natural history of Hurler syndrome, which
involves steep neurocognitive decline to a profoundly
impaired state by age 4, if not sooner.36 All of the patients
who demonstrated increases in IQ two years after treatment
had at least 50% reduction in CSF NRE I0S6 across the four
time points. This finding aligns with the idea that the focus on
the nonreducing end of the GAG may be a more sensitive and
specific biomarker than simply measuring the total extent of
GAG accumulation,25 as NRE may have some association
with key clinical manifestations.
Why was there a significant relationship between reduction
in NRE I0S6 and percent change in IQ, but not between NRE
I0S0 and IQ? The different statistical properties of these two
biomarkers are likely a major reason. First, a plot of both
NREs by age shows that I0S6 is more plentiful than I0S0, even
though both decrease over time (reflected by age) after
initiation of treatment (Figure S4). Thus, a larger sample size
would likely be needed to detect a relationship between I0S0
and IQ, as the slope for this variable is smaller than I0S6.
Second, there are differences in variability between I0S0 and
I0S6. The observed data showed a greater range in change in
IQ scores among those with 100% I0S0 reduction, leading to a
lower slope relative to the relationship between I0S6 and IQ.
Intravenous ERT is presumed not to cross the blood–brain
barrier to treat the neurologic pathology of Hurler
syndrome.8,14 In line with this theory, there is clinical
evidence of greater cumulative incidence of classic CNS
structural manifestations of Hurler syndrome when IV ERT is
the sole treatment, instead of HCT.6 Notably, despite the
evidence that HCT has better ability to halt CNS disease
progression than ERT, in the present study many CSF
abnormalities showed improvement even before HCT. Not
only did opening pressure decrease, but also there were
significant decrements in NRE as well as HCIIT between time
points 1 and 2, which are prior to HCT, raising the possibility
that these improvements were facilitated with IT therapy.
They also suggest that IT therapy may be associated with
decreased CSF GAG. Further, as HCIIT has been shown to be
a biomarker in several MPS diseases,37–39 these findings
suggest HCIIT may be a useful surrogate marker of GAG
accumulation.
The reductions in biochemical abnormalities in the CSF
prior to transplant, i.e., during only IT and intravenous ERT
therapy, align with reports of some benefit of IT ERT in
humans with the attenuated phenotypes of MPS I.19,21 In one
report, CSF GAG was reduced from slightly above normal:
13.3 mg/L (NV < 12 mg/L) to normal levels (10.3 mg/L) after
therapy.19 That patient did not have elevations in CSF
opening pressure at any point. In another report, the patient
showed significantly improved memory and adaptive func-
tioning, and mildly improved attention and IQ following
treatment.21
The most notable limitation of this study is a lack of a
comparison CSF from a group that received only intravenous
ERT and HCT. Such a comparison would possibly allow for
increased clarification of what changes resulted from IT
therapy, but the frequency of CSF collection that would be
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needed for such a trial is not justified in patients who are not
receiving intrathecal treatment. However, we emphasize that
the unique access to serial CSF samples in this study enabled a
separate investigation of a potential relationship between
biomarker change and clinical outcome.
In terms of other limitations, enrollment bias may have
influenced these results, as data were collected at a single
institution, which has the potential to exclude patients whose
health status or family resources prohibit travel. Also,
previous studies of HCT for pediatric neurodegenerative
metabolic diseases have noted that undergoing retransplanta-
tion for failed engraftment involves both repeated exposure to
preparative regimens known to affect the CNS and extended
delay in the arrest of the disease process, which can exacerbate
neurocognitive decline.18,40 However, all results remained
largely the same when the patient who underwent a second
transplant was excluded from analyses. While age was not a
significant predictor of IQ change in this group, it may have
been challenging to detect age-related differences given the
small sample and the fact that this entire group was generally
young upon initiation of treatment (Table S4).
The findings of this study indicate that CSF biomarkers are
responsive to therapy and that a possible relationship exists
between real-time biomarker response and patients’ longer-
term neurocognitive outcomes. This latter finding is impor-
tant in light of the proliferation of new therapies aimed at
reducing the neurocognitive and somatic disease burden that
persists even when all treatment guidelines are followed.
While there is extensive evidence that earlier treatment yields
better clinical outcomes in Hurler syndrome8,12,13,34 predic-
tions of neurocognitive outcomes based on timing of
treatment are unreliable due to the multitude of factors,
known and unknown, affecting the clinical course. Identifying
biomarkers that correlate with neurocognitive function may
expand the possibilities for disease monitoring, predicting the
outcomes, and developing targeted therapies to yield
improved clinical results.
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